發(fā)布時(shí)間：2018-01-31 12:37

  本文關(guān)鍵詞： 枳殼 胃泌素 乙酰膽堿 胃動(dòng)素 P物質(zhì) 血管活性腸肽　出處：《時(shí)珍國(guó)醫(yī)國(guó)藥》2017年05期 　論文類型：期刊論文

【摘要】：目的研究枳殼水煎液及其主要活性成分對(duì)脾虛模型大鼠血清胃泌素(GAS)、血漿乙酰膽堿(ACh)、胃動(dòng)素(MTL)、P物質(zhì)(SP)和血管活性腸肽(VIP)的影響。方法以苦寒瀉下加饑飽失常法復(fù)制大鼠脾虛模型,枳殼水煎液及其主要活性成分分別灌胃給藥后,采用ELISA法檢測(cè)大鼠血清胃泌素、血漿乙酰膽堿、胃動(dòng)素、P物質(zhì)和血管活性腸肽的含量變化,觀察各組給藥后對(duì)脾虛模型大鼠胃腸激素的影響。結(jié)果與空白對(duì)照組比較,模型組大鼠中ACh、GAS、MTL和SP含量顯著降低(P0.01),而VIP含量則顯著升高(P0.05)。各組給藥后,柚皮苷低、中、高劑量組血漿中ACh含量,柚皮苷低劑量組血漿中SP含量和柚皮苷低劑量組中VIP含量與模型組比較顯著降低(P0.05,P0.01),而柚皮苷中、高劑量組血漿中SP含量和柚皮苷低、中劑量組血清中GAS含量則較模型組顯著升高(P0.05,P0.01);新橙皮苷低劑量組血漿中ACh含量較模型組顯著降低,而新橙皮苷高劑量組血漿中ACh含量,新橙皮苷低、中、高劑量組血漿中SP含量,新橙皮苷中、高劑量組血漿中MTL含量和新橙皮苷低、中、高劑量組血清中GAS含量則較模型組顯著升高;兩個(gè)單體組合物低劑量組血漿中ACh含量和兩個(gè)單體組合物低、中劑量組血漿中VIP含量與模型組比較顯著降低,而兩個(gè)單體組合物中、高劑量組血漿中ACh含量,兩個(gè)單體組合物高劑量組血漿中SP含量,兩個(gè)單體組合物高劑量組血漿中MTL含量和兩個(gè)單體組合物低、中、高劑量組血清中GAS含量則較模型組顯著升高;枳殼水煎液低劑量組血漿中ACh含量與模型組比較顯著降低,而枳殼水煎液高劑量組血漿中MTL含量和枳殼水煎液低、中、高劑量組血清中GAS含量則較模型組顯著升高。結(jié)論枳殼可能通過(guò)升高血清中GAS、血漿中ACh、MTL、SP含量和抑制VIP的分泌來(lái)促進(jìn)胃腸運(yùn)動(dòng),這可能是枳殼治療胃腸動(dòng)力障礙性疾病的機(jī)制之一。
[Abstract]:Objective to study the effects of Fructus Aurantii decoction and its main active components on serum gastrin (gastrin), acetylcholine (ache) and motilin (MTL) in rats with spleen deficiency. Methods the spleen deficiency model of rats was induced by cold diarrhea plus hunger and satiety. The decoction of Fructus Aurantii Fructus Aurantii and its main active components were given orally. The changes of serum gastrin, plasma acetylcholine, motilin substance P and vasoactive intestinal peptide were detected by ELISA. To observe the effect of each group on gastrointestinal hormones in rats with spleen deficiency. Results compared with the blank control group, the MTL and SP contents of GASA in the model group were significantly lower than those in the control group (P 0.01). However, the content of VIP increased significantly (P 0.05). After administration of naringin, the content of ACh in plasma was low, medium and high dose groups. The SP content in plasma of naringin low dose group and VIP content in naringin low dose group were significantly lower than those in model group, while naringin was significantly decreased in naringin group. The content of SP and naringin in plasma of high dose group was lower than that of model group, while the content of GAS in serum of middle dose group was significantly higher than that of model group. Compared with the model group, the plasma ACh content in the low dose group was significantly lower than that in the model group, while the content of ACh in the plasma of the high dose group was lower than that in the model group, and the content of SP in the plasma was lower in the high dose group and the content of SP in the plasma was lower in the high dose group. The content of MTL and neopeperidin in plasma of high dose group was lower than that of model group, while the content of GAS in serum of high dose group was significantly higher than that of model group. The plasma ACh content and two monomer compositions were lower in the two monosomic compositions than in the model group, while the VIP content in the plasma in the middle dose group was significantly lower than that in the model group, while in the two monomer compositions, the content of VIP in the plasma was lower than that in the model group. ACh content in plasma of high dose group, SP content in plasma of high dose group of two monomer compositions, MTL content in plasma of high dose group of two monomer compositions and two monomer compositions were low and medium. The serum GAS content in the high dose group was significantly higher than that in the model group. Compared with the model group, the plasma ACh content in the low dose group of Fructus Aurantii decoction was significantly lower than that in the model group, while the content of MTL in the plasma and the decoction of Fructus Aurantii in the high dose group were lower and lower than those in the model group. The GAS content in serum of high dose group was significantly higher than that of model group. Conclusion it is possible that ACh-MTL in serum and plasma of Fructus aurantii aurantii can be increased. Sp content and inhibition of VIP secretion to promote gastrointestinal motility may be one of the mechanisms of Fructus Aurantii Fructus Aurantii in the treatment of gastrointestinal motility disorders.
【作者單位】： 江西中醫(yī)藥大學(xué)現(xiàn)代中藥制劑教育部重點(diǎn)實(shí)驗(yàn)室;
【基金】：國(guó)家自然科學(xué)基金(No.81460575;No.81260612)
【分類號(hào)】：R285.5;R-332
【正文快照】： 胃腸動(dòng)力障礙是眾多功能性胃腸病如胃食管反流、功能性消化不良及功能性便秘等共同的病理變化[1]。隨著生活節(jié)奏的加快,精神壓力的加重,胃腸動(dòng)力障礙性疾病發(fā)病率劇增,嚴(yán)重影響了患者的生活質(zhì)量。現(xiàn)代醫(yī)學(xué)認(rèn)為,人和動(dòng)物內(nèi)存在內(nèi)分泌神經(jīng)免疫網(wǎng)絡(luò),這一網(wǎng)絡(luò)集三大信息傳遞于一體

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 史琴;沈祥春;;小建中湯有無(wú)飴糖對(duì)實(shí)驗(yàn)性脾虛證小鼠血管活性腸肽的影響[J];時(shí)珍國(guó)醫(yī)國(guó)藥;2010年05期

2 尤勝義;杜寶恒;馬麗云;吳咸中;張集圣;;腸梗阻家兔血管活性腸肽改變及大承氣湯對(duì)其的影響[J];中西醫(yī)結(jié)合雜志;1991年03期

3 徐穎,張祖志,方正清,許冠蓀;半夏瀉心湯對(duì)應(yīng)激性胃黏膜損傷大鼠血管活性腸肽含量的影響[J];中醫(yī)藥臨床雜志;2004年02期

4 楊國(guó)漢;胡德耀;戴裕光;卿玉玲;秦少容;;藿香正氣液對(duì)大鼠血管活性腸肽的影響[J];中國(guó)醫(yī)院藥學(xué)雜志;2006年08期

5 彭騰;賈波;彭成;劉興隆;張楠;賀小芳;;白術(shù)茯苓湯調(diào)控脾虛大鼠血管活性腸肽有效部位的化學(xué)成分研究[J];中藥材;2009年02期

6 郭明章;黃穎;李宇航;鐘相根;吳宜芬;周冠芬;;桔梗對(duì)慢性阻塞性肺疾病大鼠不同組織血管活性腸肽(VIP)含量的影響[J];中華中醫(yī)藥學(xué)刊;2009年04期

7 楊淑萍;胡運(yùn)蓮;劉俊瓊;;易激膠囊對(duì)腹瀉型腸易激綜合征模型大鼠血管活性腸肽和肥大細(xì)胞表達(dá)的影響[J];湖北中醫(yī)藥大學(xué)學(xué)報(bào);2011年01期

8 楊蜀蓮,童章燕,左紅,高玉紅,侯雪,陳元方;急性腦缺血時(shí)鼠腦微血管血管活性腸肽的變化[J];中國(guó)醫(yī)學(xué)科學(xué)院學(xué)報(bào);1991年03期

9 馬淑穎;朱生梁;程艷梅;孫永順;張文靜;孫曼萍;黃雨稼;;疏肝和胃方對(duì)混合反流性食管炎大鼠一氧化氮合酶和血管活性腸肽的影響[J];山西中醫(yī);2006年01期

10 李冬華;李春淼;李伍善;鄒志東;張炎;;痛瀉要方對(duì)腸易激綜合征模型大鼠血管活性腸肽的影響[J];時(shí)珍國(guó)醫(yī)國(guó)藥;2007年09期

相關(guān)會(huì)議論文 前1條

1 時(shí)昭紅;張介眉;郝建軍;;調(diào)中顆粒對(duì)反流性食管炎大鼠食管黏膜P物質(zhì)、一氧化氮合酶和血管活性腸肽的影響[A];中華中醫(yī)藥學(xué)會(huì)脾胃病分會(huì)第二十次全國(guó)脾胃病學(xué)術(shù)交流會(huì)論文匯編[C];2008年

，

本文編號(hào)：1479078